The results were even more auspicious when the investigators stratified vaccinated subjects by antibody responder status: subjects who successfully mounted an immunological response to the vaccine enjoyed statistically significant benefits as measured with the IGA, the two motor function subscales of the MDS - UPDRS, and the Parkinson's Disease
Questionnaire (PDQ - 39) of quality of life (though not on the PD Non-Motor Symptoms
Questionnaire (NMS - Quest / PD - NMS)-RRB-, while no benefit was observed in
nonresponders on any scale (Table 1).